Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - For the primary ...

What happened?It's been a week to remember for shareholders of Vertex Pharmaceuticals (NASDAQ: VRTX), as the cystic fibrosis leaderonce again received some great news from across the pond, which it ...

Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday. The company's revenue came in at $2.97 billion versus estimates ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...

Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Vertex reported quarterly earnings of 15 cents per ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...